High density lipoprotein complexes as delivery vehicles for anticancer drugs
Related Experiment Video
Updated: Sep 30, 2026

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
Published on: February 9, 2019
Andras G Lacko1, Maya Nair, Sulabha Paranjape
1Institute for Cancer Research, Department of Molecular Biology and Immunology, University of North Texas Health Science Center, Fort Worth 76107, USA. alacko@hsc.unt.edu
Materials And Methods:
Recombinant high density lipoprotein (rHDL) particles were prepared with defined composition (phosphatidylcholine, apolipoprotein A-1, cholesterol and cholesteryl esters) and a molecular weight of approximately 187,000 kdaltons. Three molecules of taxol per rHDL particle were incorporated into these rHDL complexes.
Results:
Cholesteryl ester and taxol (HDL core components,) were taken up efficiently by several cancer cell lines compared to transformed normal ovarian cells (HGL5) used as the control. Immunoblotting with the scavenger receptor (SR-B1) antibody revealed strong immunoreactivity of several cancer cell lines.
Conclusion:
Our studies indicated that rHDL complexes can be used as efficient drug delivery vehicles due to the ability of cancer cells to acquire HDL core components. Targeting of anticancer drugs as components of the rHDL complex could result in reduction of toxic side-effects during chemotherapy.
Related Concept Videos
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Modified-Release Drug Delivery Systems: Site-Targeted
Receptor-mediated Endocytosis
Drug Distribution: Tissue Binding
For...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents

